1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2022, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
- GC Biopharma Corp
- KM Biologics Co Ltd
- PlateletBio
- Sanofi
- TagCyx Biotechnologies
- Takeda Pharmaceutical Co Ltd
- TargED Biopharmaceuticals BV
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
- caplacizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cinaxadamtase alfa - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GC-1126A - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Thrombotic Thrombocytopenic Purpura - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Microlyse - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
- Product Description
- Mechanism Of Action
- TAGX-0004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
- Featured News & Press Releases
- Feb 14, 2022: Sanofi files NDA for rare blood disease drug in Japan
- Jul 02, 2021: Sanofi to present on Cablivi at ISTH 2021
- Nov 12, 2020: NICE recommends innovative treatment for severe blood disorder for NHS use
- Apr 30, 2020: CHMP adopts positive opinion for treatment of acquired thrombotic thrombocytopenic purpura with caplacizumab
- Mar 02, 2020: Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
- Dec 17, 2019: Sanofi wins prestigious drug discovery award for innovative Rare Blood Clotting Disorder treatment
- Nov 06, 2019: New data on Cablivi to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
- Mar 21, 2019: Biologics by McKesson expands specialty pharmacy capabilities to serve patients with rare and complex conditions
- Feb 07, 2019: FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder
- Jan 09, 2019: New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder
- Oct 30, 2018: Pharm-Olam conducts pivotal orphan disease trial, leads to first therapeutic approved for the treatment for acquired thrombotic thrombocytopenic purpura
- Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
- Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder
- Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)
- Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by GC Biopharma Corp, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by PlateletBio, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TagCyx Biotechnologies, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TargED Biopharmaceuticals BV, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, 2022
- Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, 2022
- Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GC Biopharma Corp
- KM Biologics Co Ltd
- PlateletBio
- Sanofi
- TagCyx Biotechnologies
- Takeda Pharmaceutical Co Ltd
- TargED Biopharmaceuticals BV
